Supplementary Information (SI) for RSC Advances. This journal is © The Royal Society of Chemistry 2025

## **Supporting information**

Ligand-free Palladium-catalyzed synthesis of 3-(2,2-dialkyl-2*H*-chromen-4-yl)-2-phenylimidazo[1,2-*a*]pyridine derivatives and evaluation of their antibacterial activity with molecular docking investigation as DNA gyrase inhibitors

Rudra Narayan Mishra, Mohammed Ansar Ahemad, Jasmine Panda, Sabita Nayak, Seetaram Mohapatra, Chita Ranjan Sahoob


<sup>a</sup>Organic Synthesis Laboratory, Department of Chemistry, Ravenshaw University, Cuttack-753003, Odisha, India <sup>b</sup>ICMR-Regional Medical Research Centre, Department of Health Research, Ministry of Health & Family Welfare, Govt. of India, Bhubaneswar-751023, Odisha, India

\*Corresponding Author

Email: sabitanayak18@gmail.com

## **Contents**

- 1. Fig S1-S63: <sup>1</sup>H, <sup>13</sup>C NMR and HRMS spectra of synthesized compounds 16(a-u)
- 2. Fig S64-S84: Molecular docking studies of 16(a-u) derivatives with E. coli DNA gyrase (PDB ID: 1AJ6)
- 3. Fig S85-S105: Molecular docking studies of 16(a-u) derivatives with S. aureus DNA gyrase (PDB ID: 3G7B)



**Fig S1**: <sup>1</sup>H NMR of *3-(2, 2-dimethyl-2H-chromen-4-yl)-2-phenylimidazo-[1,2-a]pyridine* **(16a)** 




Fig S2: <sup>13</sup>C NMR of 3-(2, 2-dimethyl-2H-chromen-4-yl)-2-phenylimidazo-[1,2-a]pyridine (16a)





Fig S3: HR-MS of 3-(2, 2-dimethyl-2H-chromen-4-yl)-2-phenylimidazo-[1,2-a]pyridine (16a)



**Fig S4**: <sup>1</sup>H NMR of *3-(2, 2-dimethyl-2H-chromen-4-yl)-7-methyl-2-phenylimidazo-[1,2-a]pyridine* (16b)




Fig S5: <sup>13</sup>C NMR of 3-(2, 2-dimethyl-2H-chromen-4-yl)-7-methyl-2-phenylimidazo-[1,2-a]pyridine (16b)




Fig S6: HR-MS of 3-(2, 2-dimethyl-2H-chromen-4-yl)-7-methyl-2-phenylimidazo-[1,2-a]pyridine (16b)





Fig S7: <sup>1</sup>H NMR of 3-(2, 2-dimethyl-2H-chromen-4-yl)-6-methyl-2-phenylimidazo-[1,2-a]pyridine (16c)



**Fig S8**: <sup>13</sup>C NMR of 3-(2, 2-dimethyl-2H-chromen-4-yl)-6-methyl-2-phenylimidazo-[1,2-a]pyridine (**16c**)





Fig S9: HR-MS of 3-(2, 2-dimethyl-2H-chromen-4-yl)-6-methyl-2-phenylimidazo-[1,2-a]pyridine (16c)



 $\textbf{Fig S10: } ^1\textbf{H NMR of } \textit{2-(4-Chlorophenyl)-3-(2,2-dimethyl-2H-Chromen-4-yl)-imidazo[1,2-a]} pyridine~\textbf{(16d)}$ 




Fig S11: <sup>13</sup>C NMR of 2-(4-Chlorophenyl)-3-(2,2-dimethyl-2H-Chromen-4-yl)-imidazo[1,2-a]pyridine (16d)




Fig S12: HR-MS of 2-(4-Chlorophenyl)-3-(2,2-dimethyl-2H-Chromen-4-yl)-imidazo[1,2-a]pyridine (16d)




Fig S13: <sup>1</sup>H NMR of 2-(4-chlorophenyl)-3-(2,2-dimethyl-2H-chromen-4-yl)-7-methylimidazo-[1,2-a]pyridine (16e)




Fig S14: <sup>13</sup>C NMR of 2-(4-chlorophenyl)-3-(2,2-dimethyl-2H-chromen-4-yl)-7-methylimidazo-[1,2-a]pyridine (16e)




Fig S15: HR-MS of 2-(4-chlorophenyl)-3-(2,2-dimethyl-2H-chromen-4-yl)-7-methylimidazo-[1,2-a]pyridine (16e)




Fig S16: <sup>1</sup>H NMR of 2-(4-chlorophenyl)-3-(2,2-dimethyl-2H-chromen-4-yl)-6-methylimidazo-[1,2-a]pyridine (16f)




Fig S17: <sup>13</sup>C NMR of 2-(4-chlorophenyl)-3-(2,2-dimethyl-2H-chromen-4-yl)-6-methylimidazo-[1,2-a]pyridine (16f)




Fig S18: HR-MS of 2-(4-chlorophenyl)-3-(2,2-dimethyl-2H-chromen-4-yl)-6-methylimidazo-[1,2-a]pyridine (16f)




Fig S19: <sup>1</sup>H NMR of 2-(4-chlorophenyl)-3-(2,2,6-trimethyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (16g)




Fig S20: <sup>13</sup>C NMR of 2-(4-chlorophenyl)-3-(2,2,6-trimethyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (16g)






Fig S21: HR-MS of 2-(4-chlorophenyl)-3-(2,2,6-trimethyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (16g)



**Fig S22**: <sup>1</sup>H NMR of *2-(4-chlorophenyl)-7-methyl-3-(2,2,6-trimethyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine* **(16h)** 



**Fig S23**: <sup>13</sup>C NMR of 2-(4-chlorophenyl)-7-methyl-3-(2,2,6-trimethyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (**16h**)




Fig S24: HR-MS of 2-(4-chlorophenyl)-7-methyl-3-(2,2,6-trimethyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (16h)





Fig S25: <sup>1</sup>H NMR of 2-(4-chlorophenyl)-6-methyl-3-(2,2,6-trimethyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (16i)



**Fig S26**: <sup>13</sup>C NMR of 2-(4-chlorophenyl)-6-methyl-3-(2,2,6-trimethyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (**16i**)




Fig S27: HR-MS of 2-(4-chlorophenyl)-6-methyl-3-(2,2,6-trimethyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (16i)




Fig S28: <sup>1</sup>H NMR of 3-(2, 2-diethyl-2H-chromen-4-yl)-2-phenylimidazo-[1,2-a]pyridine (16j)




Fig S29: <sup>13</sup>C NMR of 3-(2, 2-diethyl-2H-chromen-4-yl)-2-phenylimidazo-[1,2-a]pyridine (16j)




Fig S30: HR-MS of 3-(2, 2-diethyl-2H-chromen-4-yl)-2-phenylimidazo-[1,2-a]pyridine (16j)




Fig S31: <sup>1</sup>H NMR of 3-(2, 2-diethyl-2H-chromen-4-yl)-7-methyl-2-phenylimidazo-[1,2-a]pyridine (16k)




Fig S32: <sup>13</sup>C NMR of 3-(2, 2-diethyl-2H-chromen-4-yl)-7-methyl-2-phenylimidazo-[1,2-a]pyridine (16k)





Fig S33: HR-MS of 3-(2, 2-diethyl-2H-chromen-4-yl)-7-methyl-2-phenylimidazo-[1,2-a]pyridine (16k)



**Fig S34**: <sup>1</sup>H NMR of *3-(2, 2-diethyl-2H-chromen-4-yl)-6-methyl-2-phenylimidazo-[1,2-a]pyridine* (**16l)** 




Fig S35: <sup>13</sup>C NMR of 3-(2, 2-diethyl-2H-chromen-4-yl)-6-methyl-2-phenylimidazo-[1,2-a]pyridine (16l)




Fig S36: HR-MS of 3-(2, 2-diethyl-2H-chromen-4-yl)-6-methyl-2-phenylimidazo-[1,2-a]pyridine (161)




Fig S37: <sup>1</sup>H NMR of 2-(4-Chlorophenyl)-3-(2,2-diethyl-2H-Chromen-4-yl)-imidazo[1,2-a]pyridine (16m)




Fig S38: <sup>13</sup>C NMR of 2-(4-Chlorophenyl)-3-(2,2-diethyl-2H-Chromen-4-yl)-imidazo[1,2-a]pyridine (16m)




Fig S39: HR-MS of 2-(4-Chlorophenyl)-3-(2,2-diethyl-2H-Chromen-4-yl)-imidazo[1,2-a]pyridine (16m)




Fig S40: <sup>1</sup>H NMR of 2-(4-chlorophenyl)-3-(2,2-diethyl-2H-chromen-4-yl)-7-methylimidazo[1,2-a]pyridine (16n)




Fig S41: <sup>13</sup>C NMR of 2-(4-chlorophenyl)-3-(2,2-diethyl-2H-chromen-4-yl)-7-methylimidazo[1,2-a]pyridine (16n)




Fig S42: HRMS of 2-(4-chlorophenyl)-3-(2,2-diethyl-2H-chromen-4-yl)-7-methylimidazo[1,2-a]pyridine (16n)




Fig S43: <sup>1</sup>H NMR of 2-(4-chlorophenyl)-3-(2,2-diethyl-2H-chromen-4-yl)-6-methylimidazo[1,2-a]pyridine (160)




Fig S44: <sup>13</sup>C NMR of 2-(4-chlorophenyl)-3-(2,2-diethyl-2H-chromen-4-yl)-6-methylimidazo[1,2-a]pyridine (160)




Fig S45: HR-MS of 2-(4-chlorophenyl)-3-(2,2-diethyl-2H-chromen-4-yl)-6-methylimidazo[1,2-a]pyridine (160)





Fig S46: <sup>1</sup>H NMR of 3-(2, 2-dipropyl-2H-chromen-4-yl)-2-phenylimidazo-[1,2-a]pyridine (16p)



**Fig S47**: <sup>13</sup>C NMR of *3-(2, 2-dipropyl-2H-chromen-4-yl)-2-phenylimidazo-[1,2-a]pyridine* (**16p**)





Fig S48: HR-MS of 3-(2, 2-dipropyl-2H-chromen-4-yl)-2-phenylimidazo-[1,2-a]pyridine (16p)



**Fig S49**: <sup>1</sup>H NMR of *3-(2,2-dipropyl-2H-chromen-4-yl)-7-methyl-2-phenylimidazo[1,2-a]pyridine* **(16q)** 







Fig S50: <sup>13</sup>C NMR of 3-(2,2-dipropyl-2H-chromen-4-yl)-7-methyl-2-phenylimidazo[1,2-a]pyridine (16q)



**Fig S51**: HR-MS of *3-(2,2-dipropyl-2H-chromen-4-yl)-7-methyl-2-phenylimidazo[1,2-a]pyridine* (**16q**)



**Fig S52**: <sup>1</sup>H NMR of *3-(2,2-dipropyl-2H-chromen-4-yl)-6-methyl-2-phenylimidazo-[1,2-a]pyridine* (**16r**)



**Fig S53**: <sup>13</sup>C NMR of *3-(2,2-dipropyl-2H-chromen-4-yl)-6-methyl-2-phenylimidazo-[1,2-a]pyridine* (**16r**)




Fig S54: HR-MS of 3-(2,2-dipropyl-2H-chromen-4-yl)-6-methyl-2-phenylimidazo-[1,2-a]pyridine (16r)




Fig S55: <sup>1</sup>H NMR of 2-(4-chlorophenyl)-3-(2, 2-dipropyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (16s)




Fig S56: <sup>13</sup>C NMR of 2-(4-chlorophenyl)-3-(2, 2-dipropyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (16s)





Fig S57: HR-MS of 2-(4-chlorophenyl)-3-(2, 2-dipropyl-2H-chromen-4-yl)-imidazo-[1,2-a]pyridine (16s)



 $\textbf{Fig S58}: \ ^{1}\text{H NMR of } 2\text{-}(4\text{-}chlorophenyl) - 3\text{-}(2,2\text{-}dipropyl-2H\text{-}chromen-4\text{-}yl)} - 7\text{-}methylimidazo} \ [1,2\text{-}a] pyridine \ \textbf{(16t)}$ 




Fig S59: <sup>13</sup>C NMR of 2-(4-chlorophenyl)-3-(2,2-dipropyl-2H-chromen-4-yl)-7-methylimidazo[1,2-a]pyridine (16t)





Fig S60: HR-MS of 2-(4-chlorophenyl)-3-(2,2-dipropyl-2H-chromen-4-yl)-7-methylimidazo[1,2-a]pyridine (16t)



**Fig S61**: <sup>1</sup>H NMR of 2-(4-chlorophenyl)-3-(2,2-dipropyl-2H-chromen-4-yl)-7-6-methylimidazo-[1,2-a]pyridine (16u)





Fig S62: <sup>13</sup>C NMR of 2-(4-chlorophenyl)-3-(2,2-dipropyl-2H-chromen-4-yl)-7-6-methylimidazo-[1,2-a]pyridine (16u)



 $\textbf{Fig S63}: \text{HR-MS of } 2\text{-}(4\text{-}chlorophenyl) - 3\text{-}(2,2\text{-}dipropyl-2H\text{-}chromen-4\text{-}yl)} - 7\text{-}6\text{-}methylimidazo} - [1,2\text{-}a]pyridine~\textbf{(16u)}$ 




Fig. S64. Docking interaction and 3D binding image of compound 16a with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S65. Docking interaction and 3D binding image of compound 16b with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S66. Docking interaction and 3D binding image of compound 16c with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S67. Docking interaction and 3D binding image of compound 16d with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S68. Docking interaction and 3D binding image of compound 16e with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S69. Docking interaction and 3D binding image of compound 16f with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S70. Docking interaction and 3D binding image of compound 16g with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S71. Docking interaction and 3D binding image of compound 16h with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S72. Docking interaction and 3D binding image of compound 16i with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S73. Docking interaction and 3D binding image of compound 16j with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S74. Docking interaction and 3D binding image of compound 16k with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S75. Docking interaction and 3D binding image of compound 16l with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S76. Docking interaction and 3D binding image of compound 16m with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S77. Docking interaction and 3D binding image of compound 16n with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S78. Docking interaction and 3D binding image of compound 160 with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S79. Docking interaction and 3D binding image of compound 16p with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S80. Docking interaction and 3D binding image of compound 16q with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S81. Docking interaction and 3D binding image of compound 16r with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S82. Docking interaction and 3D binding image of compound 16s with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S83. Docking interaction and 3D binding image of compound 16t with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S84. Docking interaction and 3D binding image of compound 16u with E. coli DNA gyrase (PDBID: 1AJ6)




Fig. S85. Docking interaction and 3D binding image of compound 16a with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S86. Docking interaction and 3D binding image of compound 16b with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S87. Docking interaction and 3D binding image of compound 16c with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S88. Docking interaction and 3D binding image of compound 16d with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S89. Docking interaction and 3D binding image of compound 16e with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S90. Docking interaction and 3D binding image of compound 16f with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S91. Docking interaction and 3D binding image of compound 16g with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S92. Docking interaction and 3D binding image of compound 16h with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S93. Docking interaction and 3D binding image of compound 16i with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S94. Docking interaction and 3D binding image of compound 16j with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S95. Docking interaction and 3D binding image of compound 16k with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S96. Docking interaction and 3D binding image of compound 16l with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S97. Docking interaction and 3D binding image of compound 16m with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S98. Docking interaction and 3D binding image of compound 16n with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S99. Docking interaction and 3D binding image of compound 160 with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S100. Docking interaction and 3D binding image of compound 16p with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S101. Docking interaction and 3D binding image of compound 16q with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S102. Docking interaction and 3D binding image of compound 16r with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S103. Docking interaction and 3D binding image of compound 16s with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S104. Docking interaction and 3D binding image of compound 16t with S. aureus DNA gyrase (PDBID: 3G7B)




Fig. S105. Docking interaction and 3D binding image of compound 16u with S. aureus DNA gyrase (PDBID: 3G7B)